Aurobindo Pharma Limited — Updates, 21-12-2024: Press Release

CuraTeQ Biologics s.r.o., a subsidiary of Aurobindo Pharma, has secured marketing authorization for its bevacizumab biosimilar, Bevqolva, from the UK's Medicines and Healthcare products Regulatory Agency (MHRA). This product will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials, aimed at treating various cancers, including metastatic colorectal and non-small cell lung cancer. With a robust pipeline of fourteen biosimilars focusing on oncology and autoimmune diseases, CuraTeQ aims to enhance patient access to high-quality treatments. This approval not only broadens Aurobindo’s portfolio in the oncology segment but also positions the company favorably in the competitive biosimilars market, potentially leading to positive growth opportunities moving forward.